Australasian Gastro-Intestinal Trials Group

Australasian Gastro-Intestinal Trials Group
Name	Australasian Gastro-Intestinal Trials Group
Formation	1990s
Type	Non-profit clinical trials group
Headquarters	Australia
Region served	Australia and New Zealand

Australasian Gastro-Intestinal Trials Group is a clinician-led cooperative research network focused on colorectal, gastric, hepatobiliary, pancreatic and other gastrointestinal cancers in Australia and New Zealand. It conducts multicenter randomized controlled trials and translational research, linking academic hospitals, cancer centres and research institutes across Sydney, Melbourne, Auckland and Wellington. The group engages investigators from oncology, surgery, pathology and biostatistics to design studies that inform practice guidelines and health policy.

History

Formed in the 1990s amid a wave of cooperative oncology initiatives, the group emerged alongside organizations such as National Cancer Institute (United States), European Organisation for Research and Treatment of Cancer, Medical Research Council (United Kingdom), Cancer Research UK, and Cooperative Trials Group (United Kingdom). Early investigators included clinicians affiliated with Royal Prince Alfred Hospital, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, St Vincent's Hospital, Sydney, Auckland City Hospital, and Christchurch Hospital. The group's trials intersected with landmark studies like those conducted by Gastrointestinal Tumor Study Group and collaborative networks such as Trans-Tasman Radiation Oncology Group and Australasian Leukaemia & Lymphoma Group. Over time the group contributed data to guideline bodies including National Comprehensive Cancer Network, European Society for Medical Oncology, and Cancer Council Australia.

Organization and Governance

The group is governed by an executive committee with representatives drawn from tertiary centres including Monash University, University of Melbourne, University of Sydney, University of Auckland, and University of Otago. Advisory input comes from biostatisticians at institutions like Cancer Institute New South Wales, Victorian Comprehensive Cancer Centre, and research units at Walter and Eliza Hall Institute of Medical Research. Ethical oversight aligns with regional Human Research Ethics Committees and regulatory engagement with agencies such as Therapeutic Goods Administration (Australia) and Medsafe (New Zealand). Governance frameworks reference standards set by Clinical Trials Transformation Initiative, Good Clinical Practice (GCP), and collaborative charters similar to those used by Cooperative Trials Group (United Kingdom).

Clinical Trials and Research Programs

The group's portfolio spans randomized controlled trials, phase II and III studies, perioperative trials, adjuvant and neoadjuvant strategies, and translational biomarker research. Trials have evaluated regimens influenced by trials from European Organisation for Research and Treatment of Cancer, National Surgical Adjuvant Breast and Bowel Project, SWOG, RTOG, Intergroup Trial consortia and incorporated endpoints referenced by U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization. Clinical sites have included Royal Brisbane and Women's Hospital, Princess Alexandra Hospital, Fiona Stanley Hospital, Wellington Hospital, and Hutt Hospital. Investigations often collaborate with pathology services such as Australian Clinical Labs and genomic platforms like Garvan Institute of Medical Research and Peter MacCallum Cancer Centre's molecular labs. The group has studied chemotherapeutic agents analogous to those trialed by European Society for Medical Oncology-associated studies and immunotherapy approaches examined in trials at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Collaborations and Partnerships

Partnerships extend to national and international entities including Cancer Australia, New Zealand Cancer Society, Australian and New Zealand Gastro-Oesophageal and Junctional Cancer Trials Group, Trans-Tasman Radiation Oncology Group, International Agency for Research on Cancer, Asia-Pacific Clinical Trials Alliance, and academic collaborators at Harvard Medical School, University of Oxford, Johns Hopkins University, University of Cambridge, and National University of Singapore. Industry collaborations have involved pharmaceutical partners similar to those working with Pfizer, Roche, Bristol Myers Squibb, Merck & Co., and medical device companies connected to surgical trials at Royal Australasian College of Surgeons. Data sharing and meta-analyses relate to initiatives with Cochrane Collaboration, PROSPERO, and cooperative meta-trial efforts linking to registries such as Australian New Zealand Clinical Trials Registry.

Education, Training, and Publications

The group runs investigator meetings, trainee workshops, and protocol development sessions that engage clinicians from Royal College of Surgeons of England-affiliated programs, postgraduate courses at University of Sydney, and fellowship schemes connected to Royal Australasian College of Physicians and Royal Australasian College of Surgeons. Educational outputs include peer-reviewed articles in journals like The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Gut (journal), and The Medical Journal of Australia. Presentations are frequent at conferences such as ASCO Annual Meeting, ESMO Congress, Gastrointestinal Cancers Symposium, ANZGOSA meetings, and national meetings hosted by Cancer Council Australia and New Zealand Medical Association.

Funding and Infrastructure

Funding sources combine investigator-initiated grants, philanthropic support, and competitive awards from entities such as National Health and Medical Research Council, Medical Research Future Fund, Philanthropy Australia, and cancer foundations including Leukaemia Foundation and Cancer Council Victoria. Infrastructure relies on clinical trial units at NHMRC Clinical Trials Centre, data management systems compatible with standards from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and biobanking resources at Australian Genome Research Facility and New Zealand Genome Service. The group leverages collaborative funding models similar to those used by European Organisation for Research and Treatment of Cancer and trial networks such as German Cancer Research Center.

Category:Clinical trial organizations